Five steps for structural reform in clinical cancer research

American Journal of Public Health

Volumn 100, Issue 4, 2010, Pages 596-603

  Matheson, Alastair ^a  

^a NONE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ADVISORY COMMITTEE; ARTICLE; CLINICAL TRIAL; FINANCIAL MANAGEMENT; FOOD AND DRUG ADMINISTRATION; HEALTH CARE POLICY; HUMAN; MEDICAL RESEARCH; METHODOLOGY; NATIONAL HEALTH ORGANIZATION; NEOPLASM; NONBIOLOGICAL MODEL; ONCOLOGY; ORGANIZATION; ORGANIZATION AND MANAGEMENT; POLITICS; UNITED STATES;

ADVISORY COMMITTEES; BIOMEDICAL RESEARCH; CLINICAL TRIALS AS TOPIC; HEALTH CARE REFORM; HUMANS; MEDICAL ONCOLOGY; MODELS, ORGANIZATIONAL; NATIONAL CANCER INSTITUTE (U.S.); NEOPLASMS; ORGANIZATIONAL CULTURE; POLITICS; RESEARCH SUPPORT AS TOPIC; UNITED STATES; UNITED STATES FOOD AND DRUG ADMINISTRATION;

EID: 77949475949     PISSN: 00900036     EISSN: 15410048     Source Type: Journal    
DOI: 10.2105/AJPH.2009.168633     Document Type: Article

References (49)

1. Obama B. Address to joint session of Congress, February 24, 2009. Available at: http://www.whitehouse.gov/the-press-office/remarks-of-presidait- barackobama-address-to-jcint-session-of-congress. Accessed December 29, 2009.
2. Feldman DR, Bosl GJ, Sheinfeld J, Motzer RJ. Medical treatment of advanced testicular cancer. JAMA. 2008; 299(6): 672-684.
3. Paoluzzi L, Kitagawa Y, Kalac M, Zain J, O'Connor OA. New drugs for the treatment of lymphoma. Hematol Oncol Clin North Am 2008; 22(5): 1007-1035.
4. Absalon MJ, Smith. FO. Treatment strategies for pediatric acute myeloid leukemia Expert Opin Pharmacother. 2009; 10(1):57-79.
5. Moen MD, McKeage K, Plosker GL, Siddiqui MA. Imatinib: a review of its use in chronic myeloid leukaemia. Drugs. 2007; 67(2): 299-320.
6. Cohen MH, Gootenberg J, Keegan P, Pazdur R. FDA drug approval summary: bevacizumab (Avastin) plus Carboplatin and Paclitaxel as first-line treatment of advanced/metastatic recurrent nonsquamous non-small cell lung cancer. Oncologist. 2007; 12(6):713-718.
7. Rock EP, Goodman V, Jiang JX, et al. Food and Drug Administration drug approval summary: sunilinib malate for the treatment of gastrointestinal stromal tumor and advanced renal cell carcinoma. Oncologist. 2007; 12(1): 107-113.
8. Kane RC, Farrell AT, Sridhara R, Pazdur R. United States Food and Drug Administration approval summary: bortezomib for the treatment of progressive multiple myeloma after one prior therapy. din Cancer Res. 2006; 12(10):2955-2960.
9. Brockstein B, Lacouture M, Agulnik M The role of inhibitors of the epidermal growth factor in management of head and neck cancer.J Natl Compr Canc Netw. 2008;6(7):696-706.
10. Sanchez SE, Trevino JG. Current adjuvant and targeted therapies for pancreatic adenocarcinoma. Curr Med Chem. 2008; 15(17): 1674-1683.
11. Danovi SA, Wong HH, Lemoine NR. Targeted therapies for pancreatic cancer. Br Med Bull. 2008; 87(1): 97-130.
12. Shojaei F, Ferrara N. Role of the microenvironment in tumor growth and in refractoriness/resistance to antiangiogenic therapies. Drug Resist Updat. 2008; 11(6): 219-230.
13. Hussein SA, Palmer DH, Spooner D, Rea DW. Molecularly targeted therapeutics for breast cancer. BioDrugs. 2007; 21 (4): 215-224.
14. Bartlett JA, Path MJ, Demasi R, et al. An updated systematic overview of triple combination therapy in antiretroviralnaive HIV-infected adults. AIDS. 2006; 20 (16): 2051-2064.
15. Finn OJ. Cancer immunology. N Engl J Med. 2008; 358(25): 2704-2715.
16. Hunder NN, Wallen H, Cao J, et al. Treatment of metastatic melanoma with autologous CD4 + T cells against NYESO-1. N Engl J Med. 2008; 358(25): 2698-2703.
17. Schilsky RL. End points in cancer clinical trials and lhe drug approval process. Clin Cancer Res. 2002;8(4):935-938.
18. Freidlin B, Korn EL, Gray R, Martin A. Multi-arm clinical trials of new agents: some design considerations. Clin Cancer Res. 2008; 14(14): 4368-4371.
19. Burzykowski T, Buyse M, PiccartGebhart MJ, et al. Evaluation of tumor response, disease control, progressionfree survival, and time to progression as potential surrogate end points in metastatic breast cancer. J Clin Oncol. 2008; 26(12): 1987-1992.
20. Pricker J. Time for reform in the drug-development process. Lancet Oncol. 2008; 9(12): 1125-1126.
21. Wardell W, Vodra W, Jones JK, Spivey RN. Past evolution and future prospects of the pharma industry and its regulation in the USA. In: Griffin JP, O'Grady J, eds. The Textbook of Pharmaceutical Mediane. 5th ed. London, England: Blackwell; 2006: 614-636.
22. National Cancer Institute. Research and funding. Available at: http:// www.cancer.gov/researchandfunding. Accessed December 29, 2009.
23. Abrams JD, Murgo A, Christian. MC. NCI's cancer therapy evaluation program: a commitment to treatment trials. In: Leong SPL, ed. Cancer Clinical Trials: Proactive Strategies. New York, NY: Springer; 2007: 31-50.
24. Mauer AM, Rich ES, Schilsky RL. The role of cooperative groups in cancer clinical trials. In: Leong SPL, ed. Cancer Clinical Trials: Proactive Strategies. New York, NY: Springer; 2007: 111-130.
25. US Food and Drug Administration, Center for Drug Evaluation and Research. Drugs. Available at: http://www.fda.gov/ cder. Accessed December 29, 2009.
26. Borchers AT, Hagie F, Keen CL, Gershwin ME. The history and contemporary challenges of the US Food and Drug Administration. Clin Ther. 2007; 29(1):1-16.
27. Ibrahim A, Hirschfeld S, Cohen MH, Griebel DJ, Williams GA, Pazdur R. FDA drug approval summaries: oxaliplatin. Oncologist. 2004; 9(1):8-12.
28. Laurent-Puig P, Taieb J. Lessons from Tarceva in pancreatic cancer: where are we now, and how should future trials be designed in pancreatic cancer? Curr Opin Oncol. 2008; 20(4): 454-458.
29. Sobrero A, Bruzzi P. Incremental advance or seismic shift? The need to "raise the bar" of efficacy for drag approval. J Clin Oncol. 2009; 27(35): 5868-5873.
30. Hawk ET, Matrisian LM, Nelson WG, et al. The Translational Research Working Group developmental pathways: introduction and overview. Clin Cancer Res. 2008; 14(18): 5664-5671.
31. National Institutes of Heallh. Road map initiative. Available at: http:// www.cancer.gov/researchandfunding/nihroadmap. Accessed December 29, 2009.
32. National Cancer Institute. Cancer Genome Atlas initiative. Available at: http://cancergenome.nih.gov. Accessed December 29, 2009.
33. National Cancer Institute. Think tanks initiative. Available at: http:// www.cancer.gov/think-tanks-cancerbiology. Accessed December 29, 2009.
34. US Food and Drug Administration. Critical Path Initiative. Available at: http://www.fda.gov/oc/initiatives/ criticalpath. Accessed December 29, 2009.
35. Woodcock J, Woosley R. The FDA Critical Path Initiative and its influence on new drug development Annu Rev Med. 2008; 59: 1-12.
36. C-Change collaboration. Available at: http ://www.o-changetogether.org. Accessed December 29, 2009.
37. Critical. Path Institute home page. Available at: http://www.c-pafh.org. Accessed December 29, 2009.
38. Biomarkers Consortium home page. Available at: http://www. biomarkersconsortium.org. Accessed December 29, 2009.
39. National Cancer Institute. President Richard Nixon's 1971 cancer initiative. Available at: http://www.dtp.nci.nih.gov/timelme/noflash/milestones/ M4-Nixon.htm. Accessed December 29, 2009.
40. National Cancer Institute. Cancer trends progress report: 2007 update. Available at: http://progressreport.cancer. gov. Accessed December 29, 2009.
41. National Cancer Institute. Connecting the nation's cancer community: an annual plan and budget proposal for fiscal year 2010. Available at: http://plan. cancer.gov. Accessed December 29, 2009.
42. Food and Drug Administration. Critical path opportunities list. Available at: http://www.fda.gov/oc/initiatives/criticalpath/reports/opp-listpdf. Accessed December 29, 2009.
43. Dagher R, Johnson J, Williams G, Keegan P, Pazdur R. Accelerated approval of oncology products: a decade of experience. J Natl Cancer Inst. 2004; 96(20): 1500-1509.
44. Spivey RN, Jones JK, Wardell W, Vodra W. The US FDA in the drug development evaluation and approval process. In; Griffin JP, O'Grady J, eds. The Textbook of Pharmaceutical Medicine. 5th ed. London, England: Blackwell; 2006: 602-613.
45. Hirschfeld S, Pazdur R. Oncology drug development: United States Food and Drag Administration perspective. Crit Rev Oncol Hematol. 2002; 42(2): 137-143.
46. Novartis. Novartis biologies. Available at: http://www.novartis.com/ research/biologies. Accessed December 29, 2009.
47. Sanofi-Aventis. Research and development Available at: http://en. sanofi-aventis.com/research-innovation/rd-key-figures/rd-key-figures.asp. Accessed December 29, 2009.
48. Winer E, Gralow J, Diller L, et al. Clinical cancer advances 2008: major research advances in cancer treatment prevention, and screening-a report from the American Society of Clinical Oncology. J Clin Oncol. 2009; 27(5): 812-826.
49. Obama B. Inaugural address, January 21, 2009. Available at: http://www. whitehouse.gov/blog/inaugural-address. Accessed December 29, 2009.